---
title: Functional Dyspepsia (FD) - Clinical Response to Montelukast in Children
nct_id: NCT02360696
overall_status: COMPLETED
sponsor: "Children's Mercy Hospital Kansas City"
study_type: OBSERVATIONAL
primary_condition: Eosinophilia
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02360696.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02360696"
ct_last_update_post_date: 2019-05-16
last_seen_at: "2026-05-12T06:14:06.987Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Functional Dyspepsia (FD) - Clinical Response to Montelukast in Children

**Official Title:** Predictors of Clinical Response to Montelukast in Children With Functional Dyspepsia

**NCT ID:** [NCT02360696](https://clinicaltrials.gov/study/NCT02360696)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 18
- **Lead Sponsor:** Children's Mercy Hospital Kansas City
- **Conditions:** Eosinophilia, Dyspepsia
- **Start Date:** 2014-08
- **Completion Date:** 2016-08
- **CT.gov Last Update:** 2019-05-16

## Brief Summary

Duodenal eosinophilia has been associated with dyspepsia in adults and the investigators have previously described the finding of duodenal mucosal eosinophilia in 71-79% of children undergoing diagnostic endoscopy. Previous studies in children have shown positive response to montelukast with approximately 50% finding complete relief and 20-30 percent showing no response.

There are a number of factors that have the potential to contribute to the observed variability in response to montelukast. These include variability in:

1. systemic drug exposure (drug absorption, biotransformation and/or elimination)
2. regulation of leukotriene biosynthesis
3. cysteinyl leukotriene receptors and downstream mediators
4. patient disease phenotype (e.g. Functional Gastrointestinal Disorder (FGID) disease classification, psychologic profile)

In this study, the investigators propose to utilize biopsy specimens stratified by drug response to identify candidate gene expression modules that will be validated in a prospective study design. The overall goal of this program is to develop a signature of montelukast response that can be applied not only to eosinophilic gastroenteritis, but more generally to other diseases, such as asthma, where the drug is widely used with variable success.

## Eligibility

- **Minimum age:** 8 Years
- **Maximum age:** 17 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Ages 8 - 17 years, inclusive
* Abdominal pain of at least 8 weeks duration and fulfilling symptom- based criteria for functional dyspepsia
* Scheduled for endoscopy following failure to respond to acid-reduction therapy
* Evidence of written parental permission (consent) and subject assent

Exclusion Criteria:

* Previous treatment with montelukast
* Treatment with corticosteroids or oral cromolyn sodium in the four weeks prior to enrollment
* Prior history or clinical signs/symptoms of chronic disease requiring regular medical care (e.g., diabetes mellitus, juvenile idiopathic arthritis, cystic fibrosis or cancer)
* Exposure within the past two weeks to drugs or natural products that induce CYP2C8/9 or CYP3A4, including amprenavir, carbamazepine, lopinavir/ritonavir, nafcillin, nevirapine, oxcarbazepine, phenobarbital, phenytoin, rifampin, St. John's Wort, or that inhibit CYP2C8/9 or CYP3A4, such as ciprofloxacin, clarithromycin, erythromycin, fluconazole, fluvoxamine, grapefruit juice, paroxetine, sertraline, sulfamethoxazole, trimethoprim
* A Body Mass Index of 30 or greater
* Non-English speaking
* Those patients who will turn 18 during the duration of the study
```

## Arms

- **Peds/Adol Pts w/ FD - CMH GI APT clinic** — Phase 1. Standard-of-Care Endoscopy to establish baseline data and immunohistochemistry studies. Additional biopsies taken for DNA and microarray analysis. If participant biopsies meet criteria (\> or = 20/hpf) and no nodularity or tumors, s/he will be eligible to move to second phase.

Phase 2. Standard of care treatment of 3 mg/kg ranitidine bid and 20 mg. montelukast each AM for three weeks. Based on response to global assessment score, participants will be placed in non-responder or responder group. Participants from the responder group will move to final phase of the study.

Phase 3: Research endoscopy to measure response to montelukast therapy. Biopsies taken for cell density counts and immunohistochemistry studies. Additional biopsies taken for DNA and microarray analysis.

## Primary Outcomes

- **Identification of a signature of montelukast response using gene expression patterns in biopsy samples from clinical responders and non-responders to montelukast.** _(time frame: Approximately 7-8 weeks)_ — Identification of patients who will benefit from montelukast therapy , allowing more efficient, and possibly more effective, care.

## Secondary Outcomes

- **Characterization a signature of montelukast response using comparison gene expression patterns in biopsy samples obtained before and after montelukast therapy in children with a positive clinical response to the drug.** _(time frame: 7-8 weeks.)_

## Locations (1)

- Children's Mercy, Kansas City, Missouri, United States

## Recent Field Changes (last 30 days)

- `results.hasResults` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `locations.children's mercy|kansas city|missouri|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02360696.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02360696*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*